Hot Growth Stocks To Buy For 2019

Wall Street is enamored with the rare-disease drugmaker Sarepta Therapeutics (NASDAQ:SRPT). Despite this stock’s 166% surge this year, after all, analysts have been quick to upgrade the biotech’s shares following a positive, albeit extremely preliminary, peak at the company’s experimental gene therapy for Duchenne muscular dystrophy (DMD) on Tuesday.  

H.C. Wainwright analyst Debjit Chattopadhyay, for example, raised his 12-month price target on the stock to a jaw-dropping $267. That overtly bullish forecast implies an upside potential of more than 85% from here. 

Image Source: Getty Images.

Is Wall Street’s faith in Sarepta well founded? Let’s dig deeper to find out. 

Orphan drugmakers are worth a premium

One of the main reasons Wall Street can’t get enough of Sarepta is because of the rising tide across the rare-disease drug market at the moment. A recent industry report by EvaluateGroup, for instance, has the orphan drug space — or drugs intended for fairly small patient populations like DMD — nearly doubling in size over the course of 2018 to 2024. As the market share leader in treatments for DMD, Sarepta is therefore primed to benefit from this period of hypergrowth.

Hot Growth Stocks To Buy For 2019: Natural Gas(NG)

Advisors’ Opinion:

  • [By Logan Wallace]

    NovaGold Resources Inc. (TSE:NG) (AMEX:NG) insider David Ottewell sold 60,309 shares of the business’s stock in a transaction dated Wednesday, September 12th. The shares were sold at an average price of C$4.85, for a total value of C$292,498.65.

  • [By Shane Hupp]

    JPMorgan Chase set a GBX 870 ($11.80) target price on National Grid (LON:NG) in a research note released on Monday. The brokerage currently has a buy rating on the stock.

  • [By Money Morning News Team]

    Canadian gold mining company NovaGold Resources Inc. (NYSE: NG) shows an even starker change in sentiment. In the last six months, the volume of short bets on the stock declined 32.75%, from 19.05 million shares to 12.81 million.

Hot Growth Stocks To Buy For 2019: New Relic, Inc.(NEWR)

Advisors’ Opinion:

  • [By Reuben Gregg Brewer, Keith Speights, and Brian Stoffel]

    That’s certainly the case with surprisingly diversified biotech company Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), out-of-favor outlet mall owner Tanger Factory Outlet Centers, Inc. (NYSE:SKT), and expanding software-maker New Relic, Inc. (NYSE:NEWR). Take the time for a deep dive, and you might find that one of these three mid-cap stocks is just right for your portfolio today.

  • [By Ethan Ryder]

    UBS Group AG lifted its stake in shares of New Relic Inc (NYSE:NEWR) by 120.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 29,623 shares of the software maker’s stock after buying an additional 16,190 shares during the quarter. UBS Group AG owned 0.05% of New Relic worth $2,195,000 as of its most recent filing with the SEC.

  • [By Motley Fool Transcribing]

    New Relic (NYSE:NEWR) Q3 2019 Earnings Conference CallFeb. 6, 2019 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Ethan Ryder]

    New Relic (NYSE:NEWR) had its target price increased by BMO Capital Markets from $95.00 to $110.00 in a report published on Tuesday, Marketbeat reports. BMO Capital Markets currently has an outperform rating on the software maker’s stock.

Hot Growth Stocks To Buy For 2019: Aclaris Therapeutics, Inc.(ACRS)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Cadence Capital Management LLC grew its stake in Aclaris Therapeutics Inc (NASDAQ:ACRS) by 12.1% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 33,286 shares of the biotechnology company’s stock after buying an additional 3,593 shares during the quarter. Cadence Capital Management LLC owned 0.11% of Aclaris Therapeutics worth $665,000 as of its most recent SEC filing.

  • [By Max Byerly]

    Aclaris Therapeutics (NASDAQ:ACRS) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

  • [By Stephan Byrd]

    Headlines about Aclaris Therapeutics (NASDAQ:ACRS) have been trending somewhat positive on Thursday, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aclaris Therapeutics earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.9638334424702 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

  • [By Shane Hupp]

    Aclaris Therapeutics Inc (NASDAQ:ACRS) Director Stephen A. Tullman bought 6,600 shares of Aclaris Therapeutics stock in a transaction that occurred on Thursday, August 23rd. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $99,000.00. Following the acquisition, the director now owns 170,357 shares of the company’s stock, valued at $2,555,355. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

  • [By Logan Wallace]

    News headlines about Aclaris Therapeutics (NASDAQ:ACRS) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aclaris Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 47.0807215270757 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *